A study testing whether a GLP-1 medicine, semaglutide, can help people reduce liver fat.

Recruiting now. Registry record last updated June 4, 2026.

Who can join: Adults 18 to 75, have nafld, BMI 27+.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2.5 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor University of VirginiaDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 50

What this study is for

Primary condition: NAFLD.

Full scientific study title: Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant.

Who can join

Age18 to 75SexAnyBMI27 or higher

Adults 18 to 75, have nafld, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Male or female age 18-75 years who received LT for any indication (i.e. NASH, hepatitis C, alcohol-induced cirrhosis, autoimmune hepatitis, etc.)
Liver transplant surgery within 8-24 weeks prior to randomization
Fasting glucose \> 125 mg/dL or presence of diabetes (HbA1c≥6.5% or use of diabetes medications) or pre-diabetes (HbA1c \>5.7%)
Ability to provide informed consent
Discharged from the hospital following LT surgery

Key exclusion criteria

BMI≤ 27kg/m2
GFR (Glomerular Filtration Rate) ≤ 25 ml/min/1.73m2
Type 1 autoimmune diabetes (by anti-GAD (glutamic acid decarboxylase) or history of ketoacidosis)
History of gastroparesis
Familial or personal history of medullary thyroid cancer or MEN (Multiple Endocrine Neoplasia) 2

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Virginia1 site

Virginia Commonwealth University
Richmond, Virginia

Follow this trial

We email you if NCT05424003 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: February 22, 2024. Expected completion: August 1, 2026. Last updated on ClinicalTrials.gov: June 4, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.